{"id":"transarterial-chemoembolization","safety":{"commonSideEffects":[{"rate":"null","effect":"Hepatotoxicity"},{"rate":"null","effect":"Pain"},{"rate":"null","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This approach allows for high concentrations of chemotherapy to be delivered directly to the tumor, while minimizing systemic side effects. The embolization component helps to reduce blood flow to the tumor, further increasing the effectiveness of the chemotherapy.","oneSentence":"Transarterial Chemoembolization involves delivering chemotherapy directly to a tumor via the bloodstream, followed by embolization to block blood flow to the tumor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:39:43.377Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma"}]},"trialDetails":[{"nctId":"NCT03937830","phase":"PHASE2","title":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-03-10","conditions":"Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma","enrollment":27},{"nctId":"NCT07489768","phase":"","title":"GNB4 and Riplet Gene Methylation Combined Detection Kit for Hepatocellular Carcinoma Recurrence Monitoring","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2026-04-01","conditions":"Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Recurrent","enrollment":162},{"nctId":"NCT03753659","phase":"PHASE2","title":"IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2019-05-09","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":30},{"nctId":"NCT07145177","phase":"PHASE1","title":"177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-03-16","conditions":"Metastatic Prostate Cancer, Prostate Cancer","enrollment":30},{"nctId":"NCT07351669","phase":"","title":"A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Zhongda Hospital","startDate":"2026-01-20","conditions":"HCC - Hepatocellular Carcinoma, TACE(Transcatheter Arterial Chemoembolization), CT","enrollment":250},{"nctId":"NCT07480382","phase":"NA","title":"Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC","status":"NOT_YET_RECRUITING","sponsor":"Hong Wu","startDate":"2026-04-01","conditions":"Initially Unresectable Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT04301778","phase":"PHASE2","title":"Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-08-24","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":5},{"nctId":"NCT04777851","phase":"PHASE3","title":"Regorafenib-pembrolizumab vs. TACE/TARE in Intermediate Stage HCC Beyond Up-to-7","status":"TERMINATED","sponsor":"Translational Research in Oncology","startDate":"2023-10-11","conditions":"Carcinoma, Hepatocellular","enrollment":45},{"nctId":"NCT05672108","phase":"PHASE2","title":"Phase II Trial of Lung Chemoemobolization","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2023-05-12","conditions":"Lung Non-Small Cell Carcinoma, Mediastinal Neoplasm, Pleural Neoplasm","enrollment":30},{"nctId":"NCT05016245","phase":"PHASE3","title":"MANDARIN (S6371)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2021-09-13","conditions":"Inoperable Hepatocellular Carcinoma","enrollment":92},{"nctId":"NCT06071052","phase":"PHASE2","title":"TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-12-01","conditions":"Liver Metastasis Colon Cancer","enrollment":21},{"nctId":"NCT07449065","phase":"","title":"CECT Features of MVI Predict Response to TACE Plus TKI in Intermediate-stage HCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC), Transarterial Chemoembolization, Microvascular Invasion (MVI)","enrollment":324},{"nctId":"NCT07302919","phase":"PHASE2, PHASE3","title":"Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2026-02-16","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":152},{"nctId":"NCT07417397","phase":"PHASE3","title":"Adjuvant TACE in HCC With High-risk Recurrence Factors","status":"RECRUITING","sponsor":"Guangxi Medical University","startDate":"2026-02-01","conditions":"Hepatocellular Carcinoma, Adjuvant, Transarterial Chemoembolization","enrollment":442},{"nctId":"NCT06261814","phase":"PHASE2","title":"Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors","status":"RECRUITING","sponsor":"john eisenbrey","startDate":"2024-08-07","conditions":"Liver Neoplasms","enrollment":266},{"nctId":"NCT07414433","phase":"","title":"Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"University of Belgrade","startDate":"2026-03-01","conditions":"Hepatocellular Carcinoma (HCC), Liver Neoplasms","enrollment":60},{"nctId":"NCT07408804","phase":"NA","title":"Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Bangladesh Medical University","startDate":"2025-04-08","conditions":"Unresectable Hepatocellular Carcinoma (HCC)","enrollment":40},{"nctId":"NCT07398664","phase":"PHASE2","title":"H101 Plus TACE for r/m HNSCC","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-02-15","conditions":"Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE","enrollment":20},{"nctId":"NCT07378709","phase":"","title":"Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of Belgrade","startDate":"2024-08-21","conditions":"Hepatocellular Carcinoma (HCC), Liver Neoplasms","enrollment":15},{"nctId":"NCT07380633","phase":"PHASE2","title":"Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-23","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":90},{"nctId":"NCT04712643","phase":"PHASE3","title":"A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-03-12","conditions":"Hepatocellular Carcinoma","enrollment":342},{"nctId":"NCT01918683","phase":"NA","title":"TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2013-07","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT07368530","phase":"","title":"Using Machine Learning to Identify Responders to TACE or HAIC for uHCC","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2015-01-01","conditions":"Unresectable Hepatocellular Carcinoma (HCC), BCLC Stage B Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Carcinoma","enrollment":3000},{"nctId":"NCT05842174","phase":"PHASE1, PHASE2","title":"Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-02-01","conditions":"Hepatocellular Carcinoma","enrollment":93},{"nctId":"NCT07320508","phase":"PHASE2","title":"Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2026-01-20","conditions":"Adenoid Cystic Carcinoma, Sinonasal Carcinoma, Epirubicin","enrollment":100},{"nctId":"NCT07314372","phase":"PHASE2","title":"FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2026-02-01","conditions":"Unresectable Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma (HCC), Liver Cancer Adult","enrollment":86},{"nctId":"NCT03778957","phase":"PHASE3","title":"A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2018-11-30","conditions":"Hepatocellular Carcinoma","enrollment":724},{"nctId":"NCT07322848","phase":"PHASE3","title":"DEB-TACE vs cTACE in HCC After TIPS","status":"RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-12-01","conditions":"Hepatocellular Carcinoma (HCC), TACE, TIPS","enrollment":206},{"nctId":"NCT07321613","phase":"","title":"Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2023-05-01","conditions":"Hepatocellular Cancer (HCC)","enrollment":545},{"nctId":"NCT07315022","phase":"PHASE4","title":"Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2024-08-01","conditions":"Enhanced Recovery After Surgery, Multimodal Analgesia, Real-world Study","enrollment":129},{"nctId":"NCT07309419","phase":"PHASE2, PHASE3","title":"A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-22","conditions":"Hepatocellular Carcinoma","enrollment":222},{"nctId":"NCT02435953","phase":"PHASE3","title":"TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Ming Zhao","startDate":"2015-02","conditions":"Hepatocellular Carcinoma, Chemoembolization, Therapeutic, Ablation Techniques, RFA","enrollment":242},{"nctId":"NCT07293468","phase":"PHASE2, PHASE3","title":"Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)","status":"RECRUITING","sponsor":"Tuen Mun Hospital","startDate":"2024-04-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":106},{"nctId":"NCT04246177","phase":"PHASE3","title":"Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-05-22","conditions":"Carcinoma, Hepatocellular","enrollment":480},{"nctId":"NCT07281664","phase":"NA","title":"Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Hepatocellular Carcinoma, Transarterial Chemoembolization","enrollment":30},{"nctId":"NCT07258199","phase":"NA","title":"TACE Treats Nodular Goiter","status":"ENROLLING_BY_INVITATION","sponsor":"Peking Union Medical College Hospital","startDate":"2025-09-01","conditions":"Nodular Goiter","enrollment":30},{"nctId":"NCT06311851","phase":"PHASE1, PHASE2","title":"Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases","status":"RECRUITING","sponsor":"Pardis Noor Medical Imaging and Cancer Center","startDate":"2025-06-01","conditions":"Cancer, Metastatic Cancer, Liver Metastases","enrollment":40},{"nctId":"NCT07239245","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk Recurrent Hepatocellular Carcinamo","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-11-12","conditions":"Resectable Hepatocellular Carcinoma With High Risk of Recurrence","enrollment":30},{"nctId":"NCT07198230","phase":"","title":"Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Ting YANG","startDate":"2025-03-01","conditions":"Diffuse Large B-Cell Lymphoma, Relapsed and Refractory, Transarterial Chemoembolization","enrollment":10},{"nctId":"NCT05751343","phase":"PHASE2","title":"Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-03-09","conditions":"Hepatocellular Carcinoma","enrollment":55},{"nctId":"NCT07230314","phase":"PHASE2","title":"Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib","status":"NOT_YET_RECRUITING","sponsor":"Jinling Hospital, China","startDate":"2025-11-30","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT07209384","phase":"PHASE2","title":"Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Junpeng Wang","startDate":"2025-10-01","conditions":"Unresectable Colorectal Cancer, Advanced Malignancy, Elderly (People Aged 65 or More)","enrollment":50},{"nctId":"NCT07204327","phase":"","title":"Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2020-10-28","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":1136},{"nctId":"NCT07204262","phase":"","title":"Trajectory-Based Prognostic Modeling in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Xu Yong, MD","startDate":"2018-01-01","conditions":"Liver Cancer","enrollment":379},{"nctId":"NCT05537402","phase":"PHASE2","title":"LOcoregional vs Systemic Therapy in Patients With BCLC Stage B HCC","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-09-27","conditions":"Hepatocellular Carcinoma","enrollment":1},{"nctId":"NCT07187284","phase":"PHASE1, PHASE2","title":"EDN Combined With TACE/HAIC and Second-Line Immune-Targeted Treatment Versus TACE/HAIC Alone in Locally Advanced HCC With Portal Vein Tumor Thrombosis After First-Line Therapy Failure: A Prospective, Multicenter, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2025-09-30","conditions":"HCC - Hepatocellular Carcinoma","enrollment":62},{"nctId":"NCT07186621","phase":"PHASE3","title":"Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-07-10","conditions":"Hepatocellular Carcinoma (HCC), Radiotherapy, Adjuvant, Immune Checkpoint Inhibitor","enrollment":286},{"nctId":"NCT06882876","phase":"PHASE1","title":"JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study","status":"ENROLLING_BY_INVITATION","sponsor":"Xiangya Hospital of Central South University","startDate":"2025-07-10","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":20},{"nctId":"NCT07183566","phase":"","title":"CT Volume Measurement of Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2025-10-01","conditions":"Hepatocellular Carcinoma (HCC), CT","enrollment":66},{"nctId":"NCT07168668","phase":"PHASE2","title":"Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-09-15","conditions":"HCC, Tace, Immunotherapy","enrollment":90},{"nctId":"NCT07160374","phase":"","title":"ThinkRadial: A Prospective Study of Transradial deTACE in HCC Patients","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2018-08-21","conditions":"Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT07154082","phase":"PHASE2","title":"Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Wei Zhang","startDate":"2025-12-30","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":27},{"nctId":"NCT04997850","phase":"PHASE1, PHASE2","title":"The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Xinrui Zhu，MD","startDate":"2020-10-01","conditions":"Hepatocellular Carcinoma Non-resectable, Transarterial Chemoembolization, Tyrosine Kinase Inhibitor","enrollment":142},{"nctId":"NCT07131501","phase":"PHASE2","title":"A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-11","conditions":"Hepatocellular Carcinoma, Immunotherapy, Preoperative","enrollment":48},{"nctId":"NCT07128251","phase":"PHASE2","title":"A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2025-08-20","conditions":"Hepatocellular Carcinoma (HCC), Immunotherapy, PD-1","enrollment":47},{"nctId":"NCT03638141","phase":"PHASE2","title":"CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-10-02","conditions":"Intermediate Stage of Hepatocellular Carcinoma, Hepatocellular Carcinoma","enrollment":21},{"nctId":"NCT06323382","phase":"","title":"Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2021-01-01","conditions":"Advanced Hepatocellular Carcinoma, Anti-PD1/PDL1 Antibody, Bevacizumab","enrollment":240},{"nctId":"NCT07109336","phase":"NA","title":"Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2025-08-01","conditions":"HCC - Hepatocellular Carcinoma","enrollment":790},{"nctId":"NCT04728633","phase":"PHASE2","title":"Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2021-09-27","conditions":"Metastatic Malignant Neoplasm in the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma AJCC V8","enrollment":28},{"nctId":"NCT06156748","phase":"","title":"CT Imaging for Guiding PA-TACE for HCC","status":"COMPLETED","sponsor":"Zhujiang Hospital","startDate":"2019-10-01","conditions":"Carcinoma, Hepatocellular","enrollment":1770},{"nctId":"NCT07065786","phase":"","title":"A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhongda Hospital","startDate":"2024-01-01","conditions":"Transcatheter Arterial Chemoembolization, Unresectable Hepatocellular Carcinoma","enrollment":550},{"nctId":"NCT07053202","phase":"NA","title":"TACE With Immune Agents for Angiogenesis in Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"The First Hospital of Hebei Medical University","startDate":"2021-10-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":140},{"nctId":"NCT07031570","phase":"","title":"Efficacy and Safety of DEB-TACE Combined With HAIC Versus HAIC Alone in Patients With Unresectable CRLM","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2025-07-01","conditions":"Colorectal Cancer Metastatic","enrollment":500},{"nctId":"NCT06990620","phase":"PHASE1","title":"TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-06","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":56},{"nctId":"NCT06741020","phase":"PHASE1, PHASE2","title":"Hepatic Arterial Infusion Chemotherapy and Immunotherapy for Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-03-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":10},{"nctId":"NCT05660213","phase":"","title":"A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":750},{"nctId":"NCT06900543","phase":"PHASE3","title":"Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere","status":"RECRUITING","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2025-04-15","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":108},{"nctId":"NCT04200417","phase":"PHASE1","title":"Chemoembolization for Lung Tumors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2019-12-13","conditions":"Lung Metastases, Endobronchial Metastases, Pleural Metastases","enrollment":10},{"nctId":"NCT06911255","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Yoon Jun Kim","startDate":"2025-04-18","conditions":"Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma","enrollment":24},{"nctId":"NCT03143270","phase":"EARLY_PHASE1","title":"A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-04-28","conditions":"Liver Cancer","enrollment":20},{"nctId":"NCT03045497","phase":"PHASE1","title":"Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2012-12-12","conditions":"Hepatocellular Carcinoma","enrollment":15},{"nctId":"NCT04472767","phase":"PHASE2","title":"Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2020-08-07","conditions":"Hepatocellular Carcinoma, HCC","enrollment":35},{"nctId":"NCT06904183","phase":"PHASE2","title":"Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2025-04-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":320},{"nctId":"NCT06909708","phase":"NA","title":"SIRT Versus cTACE for Unresectable HCC (CHANCE2506)","status":"RECRUITING","sponsor":"Zhongda Hospital","startDate":"2025-04-03","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":108},{"nctId":"NCT06916546","phase":"","title":"SIRT or TACE Plus Lenvatinib and PD-(L)1 Inhibitor in High Burden HCC","status":"COMPLETED","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2022-06-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":238},{"nctId":"NCT06844357","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.","status":"RECRUITING","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","startDate":"2025-03-27","conditions":"HCC","enrollment":300},{"nctId":"NCT06503250","phase":"","title":"A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2024-07-19","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":113},{"nctId":"NCT06881446","phase":"","title":"Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/tyrosine Kinase Inhibitors with or Without TACE for Advanced HCC with Vascular Invasions","status":"RECRUITING","sponsor":"Zhongda Hospital","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":1200},{"nctId":"NCT06876753","phase":"","title":"Regional Lymph Node Metastasis and Survival Outcomes in Advanced HCC","status":"RECRUITING","sponsor":"Zhongda Hospital","startDate":"2018-06-01","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":300},{"nctId":"NCT05319431","phase":"PHASE2","title":"A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-28","conditions":"Unresectable, Non-metastatic Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT06371157","phase":"PHASE3","title":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-08-02","conditions":"Hepatocellular Carcinoma","enrollment":469},{"nctId":"NCT03895359","phase":"PHASE3","title":"Transarterial Chemoembolization (TACE) Versus TACE Plus Stereotactic Body Radiation Therapy (SBRT) in Liver Carcinoma","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2019-05-27","conditions":"Hepatocellular Carcinoma","enrollment":128},{"nctId":"NCT01648023","phase":"PHASE2","title":"Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin","status":"COMPLETED","sponsor":"Robert C. Martin","startDate":"2012-07","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":49},{"nctId":"NCT06478719","phase":"PHASE1, PHASE2","title":"To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization","status":"RECRUITING","sponsor":"Febico Biomedical Corp.","startDate":"2024-06-24","conditions":"Hepatocellular Carcinoma","enrollment":120},{"nctId":"NCT06848556","phase":"PHASE1, PHASE2","title":"Evaluate the Effect of Tirazamine on Primary Liver Cancer.","status":"TERMINATED","sponsor":"Zhejiang Raygene Pharmaceuticals Co., Ltd","startDate":"2021-05-14","conditions":"Hepato Cellular Carcinoma (HCC)","enrollment":16},{"nctId":"NCT06038552","phase":"","title":"Comparison of Clinical Efficacy of Liver Resection, RFA, TACE, and Drug Therapy in Patients with GIST LM","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2002-01-01","conditions":"GIST, Malignant, Liver Metastases","enrollment":238},{"nctId":"NCT04268888","phase":"PHASE2, PHASE3","title":"Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC","status":"SUSPENDED","sponsor":"The Clatterbridge Cancer Centre NHS Foundation Trust","startDate":"2019-05-08","conditions":"Hepatocellular Carcinoma","enrollment":522},{"nctId":"NCT06397235","phase":"PHASE2","title":"DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-05-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":130},{"nctId":"NCT06823050","phase":"","title":"A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC","status":"NOT_YET_RECRUITING","sponsor":"Xuhua Duan","startDate":"2025-03-01","conditions":"Hepatocellular Carcinoma","enrollment":59},{"nctId":"NCT06492395","phase":"PHASE3","title":"Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT","status":"RECRUITING","sponsor":"Second Affiliated Hospital of Guangzhou Medical University","startDate":"2024-08-01","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":178},{"nctId":"NCT02936388","phase":"PHASE2","title":"Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2016-01","conditions":"Uveal Melanoma","enrollment":108},{"nctId":"NCT05911633","phase":"NA","title":"BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)","status":"RECRUITING","sponsor":"Terumo Europe N.V.","startDate":"2024-02-27","conditions":"Hepatocellular Carcinoma Non-resectable","enrollment":50},{"nctId":"NCT05776875","phase":"PHASE2","title":"Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC","status":"TERMINATED","sponsor":"Yale University","startDate":"2023-06-07","conditions":"Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma","enrollment":3},{"nctId":"NCT05301842","phase":"PHASE3","title":"Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-03-28","conditions":"Hepatocellular Carcinoma","enrollment":760},{"nctId":"NCT06114082","phase":"PHASE2","title":"TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2023-04-28","conditions":"Hepatocellular Carcinoma, Liver Cancer","enrollment":128},{"nctId":"NCT04803994","phase":"PHASE3","title":"The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma","status":"RECRUITING","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2021-07-06","conditions":"Hepatocellular Carcinoma","enrollment":434},{"nctId":"NCT02724540","phase":"PHASE2","title":"Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2016-03","conditions":"Neuroendocrine Tumor, Malignant, Liver Metastases","enrollment":162},{"nctId":"NCT02221778","phase":"PHASE2","title":"SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2014-08","conditions":"Carcinoma, Hepatocellular","enrollment":25},{"nctId":"NCT06715072","phase":"","title":"Study on the Efficacy and Safety of Transarterial Chemoembolization Combined with Targeted Immunotherapy in Patients with Unresectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Yao Xie","startDate":"2025-07","conditions":"Unresectable Liver Cancer","enrollment":70},{"nctId":"NCT03145558","phase":"PHASE2","title":"TATE Versus TACE in Intermediate Stage HCC","status":"TERMINATED","sponsor":"Teclison Ltd.","startDate":"2017-12-05","conditions":"Carcinoma, Hepatocellular","enrollment":6}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"DEPRESSED MOOD"},{"count":1,"reaction":"LIVER ABSCESS"},{"count":1,"reaction":"PYREXIA"},{"count":1,"reaction":"SEPSIS"}],"_approvalHistory":[],"publicationCount":6229,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TACE"],"phase":"phase_3","status":"active","brandName":"Transarterial Chemoembolization","genericName":"Transarterial Chemoembolization","companyName":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","companyId":"london-health-sciences-centre-research-institute-or-lawson-research-institute-of","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Transarterial Chemoembolization involves delivering chemotherapy directly to a tumor via the bloodstream, followed by embolization to block blood flow to the tumor. Used for Hepatocellular carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}